Recent News

SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?

SITC 2022: Avelumab-Based Combination Therapy for Advanced Urothelial Carcinoma

SITC 2022: Cellular Research May Lead to the Next Generation of Therapies for Myeloma

Neoadjuvant Cemiplimab-rwlc Treatment of Cutaneous Squamous Cell Carcinoma

SITC 2022: Neoantigen-Specific Antibody Responses in Metastatic Triple-Negative Breast Cancer

SITC 2022: First-Line Antigen Presenting Cell Activator Plus Pembrolizumab Under Study in NSCLC

SITC 2022: Ongoing Study of Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

SITC 2022: Can ctDNA Help to Predict Therapeutic Outcomes in Patients With NSCLC?

SITC 2022: Identifying Markers for Grade 3 Toxicities in Patients With LBCL Treated With Axicabtagene Ciloleucel

AASLD 2022: Using MRI to Predict Response to Combination Immunotherapy for Liver Cancer

FDA Approves Combination Immunotherapy Regimen Plus Chemotherapy for Metastatic Lung Cancer

SITC 2022: Use of Cell-Free DNA Monitoring to Predict Outcomes With Immunotherapy in NSCLC

SITC 2022: Antigen-Specific Memory CD8-Positive T Cells Target BCMA to Treat Multiple Myeloma

SITC 2022: Anakinra Prophylaxis and Toxicity of Axicabtagene Ciloleucel in Resistant LBCL

SITC 2022: Neoadjuvant Combination of Radiotherapy and Pembrolizumab in Triple-Negative Breast Cancer

SITC 2022: Phase II Study of Vudalimab for Metastatic Castration-Resistant Prostate Cancer

SITC 2022: Phase II Trial Update on Vaccine Plus Pembrolizumab in Resistant Bladder Cancer

ASTRO 2022: Stereotactic Ablative Radiotherapy Plus Durvalumab for Early-Stage NSCLC

Cempilimab-rwlc Plus Chemotherapy Receives FDA Approval in NSCLC

ASTRO 2022: Salvage Radiotherapy for Advanced B-Cell NHL After CAR T-Cell Therapy

FDA Brief: Bispecific Antibody Receives Breakthrough Therapy Designation in Resistant Myeloma

Neoadjuvant Use of Ipilimumab Plus Nivolumab and Chemoradiotherapy for NSCLC

ASTRO 2022: Can Adding Radiotherapy to Immunotherapy Improve Outcomes in Advanced Liver Cancer?

SLAMF7 Antigen and Myeloma: Therapeutic Target for Antibody-Based and Cellular Immunotherapy?

ASTRO 2022: Can Bridging Radiotherapy Reduce Toxicity of Immunotherapy for Resistant B-Cell Lymphoma?

Daratumumab-Based Chemoimmunotherapy for Multiple Myeloma: Focus on Advanced Renal Failure

ASTRO 2022: 2-Year KEYNOTE-799 Update on Pembrolizumab Plus Chemoradiotherapy in Stage III NSCLC

FDA Brief: Teclistamab-cqyv Granted Accelerated Approval in Resistant Myeloma

CD38-CAR Natural Killer Cells: Potential Immunotherapy Target in Multiple Myeloma?

Durvalumab Plus Tremelimumab Receives FDA Approval in Treatment of Advanced Liver Cancer

Tisagenlecleucel Infusion in Lymphoma: Focus on Coagulation and Fibrinolytic Parameters

FDA Brief: Fast Track Designation Granted to STAT3 Inhibitor in Liver Cancer

SOHO 2022: How Does CAR T-Cell Therapy Measure Up to ASCT in Advanced DLBCL?

Overall Survival Update on Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer

Shorter Duration of Treatment With Nivolumab Plus Ipilimumab in Advanced NSCLC

FDA Brief: Priority Review for Sacituzumab Govitecan in HR-Positive, HER2-Negative Metastatic Breast Cancer

Adjuvant Nivolumab in Resected Merkel Cell Carcinoma: Interim Results From Phase II Trial

SOHO 2022: Update From CARTITUDE-2 of Ciltacabtagene Autoleucel in Multiple Myeloma

RATIONALE-301: Final Analysis Shows Benefit of Tislelizumab in Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma: Phase III Results Support Novel Doublet

SOHO 2022: Clinical Overview of CD20/CD3 Bispecific Antibodies in B-Cell Lymphoma

Blocking CD73 With Oleclumab in Combination Therapy for Triple-Negative Breast Cancer

Phase III LEAP-002 Study of Lenvatinib Alone or With Pembrolizumab in Advanced Liver Cancer

BCMA-Targeted CAR T-Cell Therapy for Older Patients With Multiple Myeloma

ASCO Quality 2022: Long-Term Quality-of-Life Impact of Lisocabtagene Maraleucel in LBCL

Are Baseline Ocular Conditions Affected by Belantamab Mafodotin Treatment in Myeloma?

ESMO 2022: Biomarker Analyses Focus on Resistance to T-DXd in Metastatic Breast Cancer

ESMO 2022: Novel Bispecific Antibody Plus Chemotherapy Under Study in NSCLC

Advanced Urothelial Carcinoma: Combination of Soluble EphB4-Human Serum Albumin Plus Pembrolizumab

FDA Approves Durvalumab in Combination Regimen for Advanced or Metastatic Biliary Tract Cancer

Immunotherapy for Advanced Biliary Tract Cancer: Tumor Mutational Burden as a Predictive Biomarker?

Durvalumab With and Without Tremelimumab in Unresectable Hepatocellular Carcinoma